ANIP ANI Pharmaceuticals, Inc. - Fundamental Analysis
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock trades at a substantial premium to Graham Number and intrinsic value, suggesting overvaluation unless sustained high growth is confirmed.
- P/E of 21.23 is below sector average of 164.77
- Price/Sales of 1.79 is reasonable for a growth stock
- Current price ($70.49) is 59% above Graham Number ($43.90)
- Intrinsic value estimate ($23.24) is significantly below current price
- Forward P/E of 6.82 is misleading due to likely one-time earnings boost
High growth expectations are priced in, but lack of earnings data and forward guidance raises uncertainty about sustainability.
- 29.6% YoY revenue growth indicates strong top-line momentum
- Forward P/E of 6.82 implies high earnings expectations
- No earnings growth data available for YoY or Q/Q
- PEG ratio unavailable, limiting growth-adjusted valuation
Historical performance has been strong, but recent technical trends suggest weakening momentum.
- 5-year return of +113.5% reflects strong historical performance
- 1-year return of +14.7% shows resilience despite recent pullback
- 6-month return of -27.9% indicates recent bearish momentum
- 1-month and 1-week returns show continued downward pressure
Despite liquidity strength, the low Piotroski score and missing Altman Z-Score indicate underlying financial fragility.
- Current ratio of 2.71 and quick ratio of 2.07 indicate strong liquidity
- Operating margin of 11.99% is healthy
- Piotroski F-Score of 4/9 signals weak financial health
- Debt/Equity ratio of 1.16 is elevated for a healthcare firm
- No Altman Z-Score available, raising distress risk
No dividend policy exists, which is typical for growth-stage biopharma firms but limits income appeal.
- No dividend yield or payout ratio
- Dividend Strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ANIP and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
Primary
|
+113.5% | +73.9% | +14.7% | -27.9% | -7.5% | -4.8% |
|
AGIO
Agios Pharmaceuticals, Inc.
Peer
|
-46.7% | +21.9% | -10.4% | -24.3% | +0.5% | +1.4% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
|
ATAI
AtaiBeckley Inc.
Peer
|
-78.7% | +117.3% | +174.8% | +16.2% | -0.9% | +14.0% |
|
AHCO
AdaptHealth Corp.
Peer
|
-72.3% | -20.2% | +10.2% | +14.1% | +0.5% | +11.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
BEARISH | $1.58B | 21.23 | 16.2% | 8.9% | $70.49 | |
|
AGIO
Agios Pharmaceuticals, Inc.
|
BEARISH | $1.63B | - | -30.2% | -% | $27.85 | |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | |
|
ATAI
AtaiBeckley Inc.
|
BEARISH | $1.51B | - | -100.8% | -% | $4.15 | |
|
AHCO
AdaptHealth Corp.
|
BEARISH | $1.44B | - | -4.3% | -2.2% | $10.6 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | MUTZ CHRISTOPHER | Officer | Sale | 5,723 | $424,617 |
| 2026-03-09 | DAVIS KRISTA | Officer | Sale | 6,572 | $488,474 |
| 2026-03-05 | CAREY STEPHEN P. | Chief Financial Officer | Sale | 7,312 | $552,031 |
| 2026-03-05 | CAREY STEPHEN P. | Chief Financial Officer | Option Exercise | 3,312 | $163,977 |
| 2026-03-03 | WALSH PATRICK D | Director | Sale | 6,000 | $445,380 |
| 2026-03-03 | GUTWERG ORI | Officer | Sale | 2,060 | $157,590 |
| 2026-03-02 | MUTZ CHRISTOPHER | Officer | Sale | 417 | $30,858 |
| 2026-02-26 | CAREY STEPHEN P. | Chief Financial Officer | Stock Award | 22,233 | $1,715,276 |
| 2026-02-26 | LALWANI NIKHIL SURESH | Chief Executive Officer | Stock Award | 75,592 | $5,831,923 |
| 2026-02-26 | GUTWERG ORI | Officer | Stock Award | 12,969 | $1,000,558 |
| 2026-02-26 | MUTZ CHRISTOPHER | Officer | Stock Award | 21,306 | $1,643,758 |
| 2026-02-26 | SHANMUGAM MUTHUSAMY | Officer and Director | Stock Award | 11,116 | $857,599 |
| 2026-02-26 | GASSERT CHAD | Officer | Stock Award | 11,116 | $857,599 |
| 2026-02-26 | COOK MEREDITH | General Counsel | Stock Award | 13,895 | $1,071,999 |
| 2026-02-26 | ROWLAND THOMAS ANDREW | Officer | Stock Award | 6,021 | $464,520 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning ANIP from our newsroom.